- Which of the following is the most appropriate long-term management plan for this patient's antithrombotic therapy?
Answer: Discontinue clopidogrel; continue aspirin and add apixaban.
This patient requires anticoagulation for atrial fibrillation (CHA₂DS₂-VASc score of 6) and is >12 months post-PCI with drug-eluting stent. Current guidelines recommend dual therapy with oral anticoagulation plus single antiplatelet therapy rather than triple therapy to reduce bleeding risk while maintaining ischemic protection. Aspirin is preferred over clopidogrel for the single antiplatelet agent in this setting. Triple therapy (option A) significantly increases bleeding risk and is not recommended for long-term use. Anticoagulation monotherapy (option C) may be considered but combination therapy is more commonly recommended. Option D uses a less optimal antiplatelet choice.
- Which of the following is the most appropriate management of his antiplatelet therapy in the perioperative period?
Answer: Hold ticagrelor 3-5 days before surgery, but continue aspirin.
This patient requires urgent surgery less than one month after receiving a drug-eluting stent (DES), placing him at very high risk for stent thrombosis if antiplatelet therapy is interrupted. The ideal scenario is to postpone elective surgery for at least 6 months. However, this surgery is urgent. The current consensus for managing dual antiplatelet therapy (DAPT) in this high-risk situation is to continue aspirin throughout the perioperative period to provide some protection against stent thrombosis, while holding the P2Y12 inhibitor (ticagrelor) for a short period (3-5 days) to reduce surgical bleeding risk. Continuing both (A) poses a very high bleeding risk. Holding both (B) poses an unacceptably high risk of stent thrombosis. Bridging therapy (D) is complex, expensive, and its efficacy in this setting is not well established; holding aspirin is also incorrect.
- Which of the following additional medications should be prescribed for long-term secondary prevention?
Answer: High-dose beta-blocker
Beta-blockers are a cornerstone of post-MI care. They have been shown to reduce mortality, reinfarction, and sudden cardiac death. They should be initiated in all patients post-MI unless contraindicated. The benefit is most established in patients with reduced ejection fraction, but they are still recommended for at least three years in patients with preserved EF. Aldosterone antagonists like spironolactone (A) and eplerenone (D) are indicated post-MI only in patients with an LVEF ≤40% and either heart failure symptoms or diabetes. Long-acting nitrates (C) are used for symptom control of angina and do not provide a mortality benefit.
- Marisol, 57, CAD, BMI 32, prediabetes, BP 138/84 on meds; walks 10 min daily. What lifestyle modification would most benefit her?
Answer: Increase moderate aerobic activity to 150 min/week
This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the patient with CAD, obesity, prediabetes, and limited activity needs to enhance exercise for risk reduction. The correct choice reflects increasing moderate aerobic activity to 150 minutes per week, which improves cardiovascular health and aligns with guidelines. A common distractor might suggest avoiding exercise, which is detrimental and contradicts recommendations for physical activity in stable CAD. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
- Which of the following is the most appropriate change to his medication regimen?
Answer: Discontinue metoprolol and start diltiazem.
The patient is experiencing common side effects of a beta-blocker (fatigue, erectile dysfunction), likely exacerbated by the negative chronotropic effect (HR 54/min). While decreasing the dose (B) might help, it could reduce the antianginal benefit. Switching to another beta-blocker like carvedilol (C) is unlikely to resolve these class-specific side effects. Prescribing sildenafil (D) addresses one symptom but not the fatigue or bradycardia, and it does not address the root cause. The most appropriate step is to switch to a different class of antianginal medication that does not cause these side effects. A non-dihydropyridine calcium channel blocker like diltiazem is an excellent alternative for symptom control in stable angina, as it also provides rate control without the beta-blocker side effect profile.
- Stable CAD, atorvastatin 80, myalgia, CK normal. Best next step?
Answer: Try rosuvastatin 5 mg
Muscle symptoms with a normal CK in a CAD patient are likely statin-associated but not dangerous, so the next step is to attempt a different statin; rosuvastatin 5 mg is reasonable. Stopping statins permanently is the tempting error: it gives up proven secondary prevention when many patients tolerate an alternative.
- Paul, 73, 2 weeks post-PCI, on aspirin+clopidogrel, reports black stools and dizziness; BP 96/60. Based on symptoms, what is next best step?
Answer: Evaluate for GI bleeding urgently while coordinating antiplatelet management
This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the patient early post-PCI on DAPT presents with black stools and hypotension, suggesting possible GI bleeding. The correct choice reflects urgent evaluation for GI bleeding while coordinating antiplatelet management, aligning with guidelines for balancing bleeding and thrombotic risks. A common distractor might suggest reassuring and continuing without evaluation, which risks missing serious hemorrhage. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
- Which of the following is the most appropriate recommendation regarding cardiac surveillance?
Answer: Continue current medical management with no routine surveillance testing.
Current guidelines do not recommend routine surveillance stress testing or anatomic imaging for asymptomatic patients with known stable CAD, including those post-revascularization (PCI or CABG). Such testing is not shown to improve outcomes and can lead to unnecessary downstream procedures and costs. Testing is reserved for patients who develop new or worsening symptoms. Since this patient is asymptomatic with a good functional capacity and her risk factors are well-managed, the most appropriate approach is to continue optimal medical therapy and clinical follow-up without further cardiac imaging.
- Which of the following is the most appropriate immediate action?
Answer: Initiate an oral beta-blocker and continue with rehabilitation.
This patient has a reduced ejection fraction post-MI and is not on a beta-blocker, which is a key component of guideline-directed medical therapy for mortality reduction and arrhythmia prevention. Asymptomatic NSVT in this setting is common and, while it is a marker of increased risk, the first step is to ensure the patient is on optimal medical therapy. Initiating a beta-blocker (e.g., carvedilol, metoprolol succinate) is the most appropriate next step. Discontinuing rehab (A) is premature. Immediate admission for an EP study (C) is not warranted for asymptomatic NSVT without optimizing medical therapy first. Amiodarone (D) is reserved for symptomatic or sustained arrhythmias and does not have a mortality benefit for primary prevention in this setting.
- Elena, 64, stable CAD, overweight, sedentary, LDL 80 on statin; angina only climbing 2 flights. What lifestyle modification would most benefit her?
Answer: Structured cardiac rehab-style aerobic exercise program
This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the overweight, sedentary patient with stable CAD and exertional angina needs lifestyle interventions to improve symptoms and risk profile. The correct choice reflects a structured cardiac rehab aerobic exercise program, which enhances functional capacity and aligns with guidelines for secondary prevention. A common distractor might suggest avoiding walking to prevent ischemia, which is counterproductive and limits beneficial activity in stable disease. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
- Robert, 66, BMI 34 with stable CAD asks lifestyle advice; smokes, BP 142/86, LDL 118 on statin. What lifestyle modification would most benefit him?
Answer: Stop smoking and start Mediterranean-style diet
This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the obese patient with stable CAD who smokes and has elevated BP and LDL requires prioritized lifestyle changes to reduce cardiovascular risk. The correct choice reflects smoking cessation and adopting a Mediterranean-style diet, which addresses major modifiable risks and aligns with evidence-based guidelines for secondary prevention. A common distractor might suggest avoiding all exercise until repeat angiography, which is unnecessary for stable disease and discourages beneficial physical activity. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
- Which of the following interventions is most likely to improve this patient's symptoms?
Answer: Referral for enhanced external counterpulsation (EECP).
This patient has refractory angina, defined as persistent symptoms despite optimal medical and revascularization therapies. He is already on three agents, and his hemodynamics limit further titration or additions of traditional drugs (e.g., ranolazine is an option, but another may be better). Enhanced external counterpulsation (EECP) is a non-invasive therapy indicated for patients with refractory angina who are not candidates for revascularization. It has been shown to improve anginal symptoms and quality of life. Adding another nitrate (C) is unlikely to help given he is on a long-acting one and is borderline hypotensive. Cardiac rehabilitation (D) is beneficial but may be difficult for a patient with class III angina to participate in fully; EECP directly targets the pathophysiology of his refractory symptoms.
- Which of the following is the most appropriate next step in this patient's management?
Answer: Proceed with coronary angiography.
This patient has lifestyle-limiting angina despite being on maximal or near-maximal doses of two antianginal agents (beta-blocker and long-acting nitrate). His heart rate and blood pressure are at the lower limits of normal, limiting further dose titration of beta-blockers or nitrates, and making the addition of a calcium channel blocker (amlodipine) problematic due to potential hypotension. While adding ranolazine (B) is an option for medical therapy, the severity of his symptoms despite an aggressive medical regimen makes him a candidate for revascularization. Therefore, the most appropriate next step is to proceed with coronary angiography to define his coronary anatomy and assess options for percutaneous coronary intervention or coronary artery bypass grafting.
- What is the most appropriate recommendation regarding his cardiac management before surgery?
Answer: Proceed with surgery without further cardiac testing.
This patient is scheduled for a low-to-intermediate risk non-cardiac surgery. According to the ACC/AHA guidelines for perioperative cardiovascular evaluation, if a patient has a good functional capacity (≥4 metabolic equivalents [METs], e.g., climbing two flights of stairs), no further cardiac testing is needed, regardless of their cardiac history. The patient is asymptomatic and on optimal medical therapy. Therefore, he can proceed with the scheduled surgery. Performing stress testing (B), echocardiography (C), or angiography (D) would not change management and is not indicated.
- Olga, 68, stable CAD, HTN, smoker, wants diet advice; LDL 92 on statin, A1c 6.1. What lifestyle modification would most benefit her?
Answer: Smoking cessation with pharmacotherapy and counseling
This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the smoking patient with stable CAD, HTN, and prediabetes seeks diet advice, highlighting the need to prioritize high-impact changes. The correct choice reflects smoking cessation with pharmacotherapy and counseling, as it offers the greatest risk reduction and aligns with guidelines. A common distractor might suggest avoiding fruits and vegetables, which contradicts heart-healthy diet recommendations and limits nutritional benefits. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
- Which of the following is the most appropriate next step in managing his dyslipidemia?
Answer: Initiate ezetimibe 10 mg daily.
This patient has statin intolerance and an LDL level above the goal of <70 mg/dL (and often <55 mg/dL in very high-risk patients like this one). While trying a different statin at a low dose (C) is a reasonable strategy for statin-associated muscle symptoms, the patient is currently unwilling to do so. Therefore, the next best step is to add a non-statin agent. Ezetimibe is the first-line non-statin agent recommended by guidelines to lower LDL cholesterol. Fenofibrate (B) primarily targets triglycerides and has limited LDL-lowering effects and no proven mortality benefit in this setting. Niacin (D) is no longer recommended for routine use due to side effects and lack of proven benefit on cardiovascular outcomes when added to a statin.
- Which of the following medication classes, when added to her current regimen, has been shown to provide additional mortality benefit in this patient population?
Answer: Sodium-glucose cotransporter-2 (SGLT2) inhibitor
Heart failure with reduced ejection fraction (HFrEF) management follows evidence-based guidelines that prioritize medications with proven mortality benefits. This patient has optimal guideline-directed medical therapy with an ACE inhibitor, beta-blocker, and mineralocorticoid receptor antagonist, plus she has diabetes—a key detail for considering newer therapeutic options.
SGLT2 inhibitors represent a breakthrough in HFrEF treatment. Large randomized trials (DAPA-HF, EMPEROR-Reduced) demonstrated that drugs like dapagliflozin and empagliflozin reduce cardiovascular death and heart failure hospitalizations in patients with HFrEF, regardless of diabetes status. The mechanism involves improved cardiac metabolism, reduced preload, and potential direct cardioprotective effects beyond glucose lowering.
Option A (ARB) would typically only be considered if the patient couldn't tolerate an ACE inhibitor, as adding both provides no additional mortality benefit and increases hyperkalemia risk. Option B (digoxin) can improve symptoms and reduce hospitalizations but doesn't reduce mortality—the RADIANCE and DIG trials showed no survival benefit. Option C (loop diuretic) treats volume overload symptoms but has no mortality benefit; this patient shows no signs of fluid retention requiring diuretic therapy.
For USMLE Step 3, remember that heart failure questions increasingly test knowledge of newer evidence-based therapies. When you see a diabetic patient with optimized HFrEF therapy, think SGLT2 inhibitors—they're now Class I recommendations in heart failure guidelines. Focus on which medications actually improve survival, not just symptoms.
- Which of the following is the most appropriate next step in the management of her hyperlipidemia?
Answer: Add ezetimibe to her current regimen.
This patient has atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes, placing her in the very high-risk category. For such patients, the LDL cholesterol goal is <70 mg/dL, and some guidelines suggest a goal of <55 mg/dL. Her LDL is 75 mg/dL on a maximally tolerated high-intensity statin. Therefore, her LDL is not at goal (A). The next step according to guidelines is to add a non-statin agent. Ezetimibe is the recommended first-choice add-on therapy. Switching to an equivalent or more potent statin (C) is unlikely to provide significant additional LDL reduction as she is already on a high-intensity dose. Fenofibrate (D) is not indicated for LDL lowering and has not been shown to reduce cardiovascular events when added to a statin in this population.
- Which of the following medications is the most appropriate addition to her regimen?
Answer: Ranolazine
This patient requires an additional antianginal agent. While beta-blockers are first-line, her history of asthma makes them relatively contraindicated, especially non-selective agents like propranolol (B). Even cardioselective beta-blockers like metoprolol (A) can potentially cause bronchospasm and should be used with caution. Nitrates (D) are an option, but ranolazine (C) is an excellent choice here. It reduces anginal frequency without affecting heart rate or blood pressure, making it a safe option in this patient who has a normal heart rate and blood pressure. It also has no adverse effects on bronchospasm or PAD symptoms.
- Which of the following is the most appropriate response to the patient's concern?
Answer: Advise him that drug allergies are not hereditary and he should continue clopidogrel.
This question tests communication and patient education. Drug allergies, particularly hypersensitivity reactions like the rash described, are idiosyncratic immune responses and are not inherited in a simple Mendelian fashion. The patient's concern is based on a misunderstanding. The most appropriate response is to educate the patient, reassure him that his wife's allergy does not confer risk to him, and advise him to continue his essential medication. Switching to ticagrelor (A) is not indicated without evidence of an allergy or treatment failure. Discontinuing clopidogrel early (B) increases the risk of stent thrombosis. Genetic testing (D) is for assessing metabolic activity (e.g., CYP2C19 status), not for predicting hypersensitivity reactions.
